Trial Profile

"A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)"

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary) ; Ciclosporin
Indications Membranous glomerulonephritis
Focus Therapeutic Use
Acronyms MENTOR

Most Recent Events

04 Jul 2019 Primary endpoint has been met. (Remission status), as per results published in the New England Journal of Medicine.
04 Jul 2019 Results evaluating the non inferiority of Rituximab to cyclosporine are published in the New England Journal of Medicine
08 Apr 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com